Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
scientific article published on 28 November 2017
Author/s
author: Luca Arcaini, John Radford, José Cabeçadas, Jan Walewski, Wojciech Jurczak, Simon A Rule, Stefano A Pileri, Thierry Lamy, Franck Morschhauser, Julia Alexeeva, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, David Belada, Elías Campo
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.